In our earlier work on acylated conjugates of the ornithine moiety of 1, we designed analogs of FR901469 to probe the requirement for the presence of the ornithine amino group and its influence on antifungal and hemolytic activity.8) As a result of these studies, it became apparent that hemolysis could be reduced by acylation with amino acid derivatives of varying spacer length, and a relationship was found between hemolysis at 1 mg/ml and the number of methylene groups in the spacer. In order to achieve good levels of in vivo efficacy, it was necessary to increase the number of amino groups close to the original ornithine amino, such that an added ornithine moiety was a particularly effective conjugate group for the natural product.8) From these early results, we next decided to examine other types of modification of the ornithine moiety of 1, and selected amidine-type analogs as being particularly attractive, due to retention of a basic group close to the position of the ornithine amino group. Since the in vivo activity of FR901469 is strong, a superior therapeutic profile should result from a reduction in hemolytic potential whilst maintaining in vivo efficacy. Table 1 shows the in vitro antifungal activity against selected Candida species and the hemolytic activity of the amidine derivatives prepared in this work. Table 2 shows activity against a strain of Aspergillus. Formamidine derivative 2 and the acetamidine derivative 3 both displayed highly potent in vitro antifungal activity. In particular, compound2 displayed superior activity towards C. albicans FP633, the strain used in our model of in vivo candidiasis.8) However, the hemolytic activity for both 2 and 3 was essentially unchanged relative to 1, indicating that further modification was required. The guanidine analog 4 retained analogs with the lowest hemolysis at 1 mg/ml. Azetidine analog 9 and pyrazolium analog 8 were particularly attractive because these analogs displayed good in vitro activity and were also highly efficacious in the in vivo candidiasis model, showing comparable efficacy to FR901469 (Table 2) . In summary, a series of amidine analogs of the unique macrocyclic lactone FR901469 have been prepared, and 
